Background
==========

Glutamate receptors are the most abundant type of excitatory neurotransmitter receptors, and they are involved in mediating common excitatory synaptic transmissions in the brain and spinal cord ([@B109]; [@B32]). These receptors are very complex in nature and more than 20 different glutamate receptors have been recognized in the mammalian central nervous system ([@B9]). Glutamate receptors are categorized into two groups: ionotropic and metabotropic. iGluRs are voltage-sensitive, whereas mGluRs are ligand-sensitive ([@B9]). The subtypes of iGluRs are named for the chemical agonists that selectively bind to these subfamily members: NMDARs, AMPARs, and KARs ([@B48]). These subtypes have different subunits: the NMDAR subunits are GluN1, GluN2A, GluN2B, GluN2C, GluN2D, GluN3A, and GluN3B; the AMPAR subunits are GluA1, GluA2, GluA3, and GluA4; and the KAR subunits are GluK1, GluK2, GluK3, GluK4, and GluK5 ([@B250]). According to their pharmacological and signal transduction properties, mGluRs are divided into three broad groups that comprise eight subtypes ([@B110]). Group I and II mGluRs have two subunits: mGluR1 and mGluR5, and mGluR2 and mGluR3, respectively. Group III mGluRs have four subunits: mGluR4, mGluR6, mGluR7, and mGluR8 ([@B278]).

Glutamate receptors are best known for their mediation of glutamate in learning and memory through plasticity, that is the modification of channel properties; enhanced glutamate neurotransmission; and gene expression ([@B23]). They are involved in the pathogenesis of a variety of neurological disorders, including anxiety, schizophrenia, and epilepsy. ([@B214]; [@B24]; [@B51]). In addition to these disorders, various studies have reported that iGluRs and mGluRs play crucial roles in the pathogenesis of NDDs, such as AD, PD, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis, and spinocerebellar ataxia ([@B72]; [@B112]; [@B188]; [@B68]; [@B15]; [@B66]; [@B124]; [@B6]; [@B244]; [@B255]; [@B260]; [@B98]; [@B79]; [@B100]; [@B305]; [@B209]).

Based on the complexity of the mechanistic progression of NDDs, elucidating the proper disease pathophysiology and therapeutics of NDDs remains a major challenge. Recently, many neurotoxic agents have been employed in experiments in order to explore cellular functions and dysfunctions ([@B123]; [@B261]; [@B1]; [@B111]; [@B192]; [@B4]; [@B117]). Their correlation with pathological characteristics of diseases via the utilization of neurotoxic agent-induced models is a helpful way to screen and discover potential therapeutic drugs for NDDs. Prior studies have also documented the actions of common neurotoxic agents that cause injury in NDD models ([@B221]; [@B29]; [@B90]; [@B170]). With respect to diverse neuronal functions, we focus on glutamate receptors as a target in neurotoxic agent-induced injury that may aid in the discovery of therapeutic drugs specifically for NDDs.

Glutamate Receptors as Potential Targets in Neurotoxic Agent-Induced NDD Models
===============================================================================

Agents That Act on iGluRs and mGluRs
------------------------------------

### Glutamate, Kainic Acid, and Domoic Acid

Glutamate, a major excitatory neurotransmitter in the central nervous system, plays a vital role in neuronal cell differentiation, migration, and survival in the developing brain, basically via facilitating the entry of Ca^2+^ ([@B146]). Kainic acid (KA), an agonist for the iGluR subtype which is known as a non-degradable analog of the excitotoxin, glutamate, offers a well-characterized model for the study of NDDs ([@B272]; [@B304]; [@B307]). DomA, a naturally occurring marine neurotoxin produced by members of the diatom genus, *Pseudo-nitzschia*, is a structural relative of KA ([@B150]).

Glutamate is capable of binding to and activating both iGluRs and mGluRs. In the brain, intracellular glutamate concentrations are in the millimolar range, and extracellular glutamate concentrations remain in the low micromolar range. These concentrations are achieved through the action of excitatory amino acid transporters that import glutamate and aspartate into astrocytes and neurons. Excess extracellular glutamate may lead to excitotoxicity *in vitro* and *in vivo* through the overactivation of iGluRs ([@B131]). In general, glutamate triggers neuroinflammation while glutamate-induced excitotoxicity may contribute to neuronal cell death in NDDs ([@B129]). Glutamate-induced excitotoxicity causes cell death, apoptosis, and autophagy in both hippocampal cells (HT22) and primary cultured hippocampal neuron cells with neurotoxicity in differentiated Y-79 cells, BV-2 cells, and PC12 cells. Mitochondrial dysfunction, oxidative damage, and neuroinflammation are also key toxic effects in the glutamate-induced neurotoxicity model ([@B22]; [@B230]; [@B268]; [@B284]; [@B42]). Numerous studies have described glutamate-induced neurotoxicity through the action of glutamate receptors. In human embryonic stem cell-derived neurons, glutamate produces NMDAR-dependent excitotoxicity. On the other hand, an NMDAR antagonist reduces glutamate-induced Ca^2+^ influx, which leads to the reduction of excitotoxicity ([@B81]). In addition, berberine-induced mitochondria and NMDAR-dependent toxicity sensitize neurons to glutamate injury. Memantine (an NMDARs antagonist) and dizocilpine (MK-801) (a non-competitive NMDARs antagonist) completely block berberine-induced neurotoxicity ([@B125]). Another study found that MK-801 and γ-D-glutamylaminomethyl sulfonic acid (a KARs/AMPARs antagonist) wholly prevents glutamate-induced impairment in hippocampal cells. An p38 MAPK inhibitor, SB203580, also prevents glutamate-induced cell damage, but an MEK1 inhibitor, PD98059, does not alter glutamate-induced cell death in the intracellular signaling pathways ([@B166]). According to the most recent research on glutamate-induced toxicity in differentiated PC12 cells, the glutamate-induced dysfunction of Ca^2+^ homeostasis is protected by FAM3A upregulation. This activity is accomplished through the inhibition of mGluR1/5-dependent Ca^2+^ release by the endoplasmic reticulum (ER) and attenuation of the stromal interaction molecule-1 (STIM1)-Orai1 channel interactions that modulate store-operated Ca^2+^ entry ([@B242]). Further, mGluR5 is expressed on astrocytes and through its activation, aquaporin 4-mediated glutamate-induced neurotoxicity causes partial mediation of astrocyte swelling. An mGluR5 agonist, (S)-3,5-dihydroxyphenylglycine (DHPG), which activates mGluR5 in cultured astrocytes, mimics the effect of glutamate. Incubation of DHPG with fenobam (an mGluR5 antagonist) negates this, and DL-threo-β-benzyloxyaspartic acid (DL-TBOA), a glutamate transporter inhibitor, does not abolish this agonistic effect ([@B227]).

The KA-induced neurotoxicity model is suitable for both *in vivo* and *in vitro* studies using rodents and several cell lines, such as BV-2 microglia, PC12 cells, and SH-SY5Y cells ([@B304]; [@B93]; [@B282]; [@B151]; [@B182]; [@B180]). By acting on KARs, KA causes neuroexcitotoxic and epileptogenic properties. KA induces behavioral changes in rodents and causes a variety of cellular events to take place, including the influx of cellular Ca^2+^, neuroinflammation, production of reactive oxygen species (ROS) and mitochondrial dysfunction. It eventually leads to neuronal apoptosis and necrosis in many regions of the brain, particularly in the hippocampal subregions, cornu ammonis 1 (CA1), cornu ammonis 3 (CA3), and hilus of dentate gyrus ([@B272]; [@B304]; [@B282]; [@B180]). Moreover, in cellular models, KA produces effects similar to those seen in rodent models ([@B93]; [@B182]). According to a recent study involving KA-induced excitotoxic hippocampal neuronal damage in rats, 2-Methyl-6-(phenylethynyl)-pyridine (a negative allosteric modulator of mGluR5) and LY354740 (an agonist of mGluR2) treatments ameliorate KA-induced neuronal cell death. Based on these results, both KARs and mGluRs may be involved in the KA-induced neuronal toxicity ([@B193]).

As a KAR agonist, DomA is considered a potent neurotoxin and is used in experimental models to cause neurotoxicity. DomA-induced neurotoxicity causes neuroinflammation, mitochondrial dysfunction, oxidative stress, apoptosis, cognitive impairment, and neuronal cell death ([@B14]; [@B39]; [@B73]; [@B150]; [@B265]). It is also employed in order to induce the symptoms of epilepsy in animal models ([@B31]). The modulation of iGluRs may play a part in DomA-induced excitotoxicity ([@B202]). In a neonatal rat model, a very low dose of DomA was shown to elicit a conditioned odor preference, and this was partly attributed to NMDARs involvement ([@B252]). According to another investigation, AMPARs/KARs primarily regulate the neurotoxic effects of DomA. NBQX (a AMPARs/KARs antagonist) completely prevents DomA-induced toxic effects, whereas the NMDARs antagonist, (2*R*)-amino-5-phosphonopentanoate (APV), only partially blocks these effects ([@B91]). The glutamate-, DomA-, and KA-induced progressions of major neurotoxicity via glutamate receptors are depicted in **Figure [1](#F1){ref-type="fig"}**.

![Glutamate receptor-mediated neurotoxic actions of glutamate, domoic acid, and kainic acid. Upon binding to glutamate receptors, all toxins produce an agonistic reaction that lead to cell death. Glu: Glutamate; KA: Kainic acid; DomA: Domoic acid; COX: Cyclooxygenase; ROS: Reactive oxygen species; and RNS: Reactive nitrogen species.](fnmol-11-00307-g001){#F1}

### 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-Methyl-4-phenylpyridinium

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a common neurotoxic agent used to induce PD in animal models. MPTP yields large variations in nigral cell loss, striatal dopamine (DA) loss, and behavioral deficits ([@B162]). 1-methyl-4-phenylpyridinium (MPP^+^), a metabolite of MPTP by monoamine oxidase-B, is also considered to be a neurotoxic agent and is also commonly used in both *in vitro* and *in vivo* PD models ([@B69]). MPTP activates the NMDARs and increases glutamate release in the striatum, which causes a large influx of Ca^2+^-induced neuronal excitotoxicity ([@B264]). The modulation of glutamate receptors by MPTP may be responsible for producing the associated neurotoxic effects. In addition, certain iGluRs antagonists have shown antiparkinsonian and anti-dyskinetic activities ([@B69]). Moreover, MPTP upregulates mGluR5 in monkey model. Chronic treatment with an mGluR5 antagonist, (3-\[(2-methyl-1,3-thiazol-4-yl) ethynyl\] pyridine) (MTEP), significantly protects dopaminergic and noradrenergic neurons from MPTP-induced toxicity ([@B218]; [@B157]). MPP^+^ interacts with NMDARs as a partial agonist and may dysregulate receptor functioning. Concerning the available research, NMDAR antagonists inhibit the actions of MPP^+^, specifically by decreasing MPP^+^-induced mitochondrial dysfunction ([@B33]). In a study, an mGluR8 agonist, (S)-3,4-Dicarboxyphenylglycine, demonstrates neuroprotective activity against MPP^+^-induced cell death in SH-SY5Y cells ([@B105]).

### Rotenone

Rotenone is a commonly used pesticide and fish toxin that impedes mitochondrial respiratory chain complex I ([@B303]). It a valuable tool for PD research and exposure to rotenone causes the induction of parkinsonism in rodents. Nowadays, rotenone is an extensively used toxin to induce neurotoxicity in both *in vitro* and *in vivo* models of PD. It causes aging-related SN dopaminergic neurodegeneration in rats ([@B273]). Rotenone potently augmented NMDA-evoked currents in rat DA neurons through a tyrosine kinase-dependent mechanism. Further study showed that the potentiation of NMDA currents by a tyrosine kinase-dependent process attenuates the voltage-dependent Mg^2+^ block of NMDA-gated channels ([@B280]). In addition, rotenone modulates mGluRs as it damages DNA through mGluR5. The selective mGluR5 antagonist protects rotenone-induced neurotoxicity by mitigating the oxidative stress-related damage to DNA associated with 8-hydroxy-2′-deoxyguanosine production, and also decreases the phosphorylation of extracellular-signal-regulated kinase activity and thioredoxin-2 expression ([@B281]).

### Methamphetamine

As a sympathomimetic amine, METH belongs to the phenethylamine and amphetamine classes of psychoactive drugs. It is abused extensively for its euphoric, stimulant, empathogenic, and hallucinogenic properties ([@B297]). As a neurotoxic agent, METH can be used to induce neurotoxicity in a study model, which may be helpful in the study of NDDs, particularly in study of PD. METH-induced neurotoxicity is characterized by a long-lasting depletion of striatal DA and serotonin as well as by damage to striatal dopaminergic and serotonergic nerve terminals ([@B120]). The principal neurotoxic effects caused by METH are oxidative stress, neuroinflammation, and apoptosis leading to neuronal cell death ([@B46]; [@B204]; [@B229]; [@B108]; [@B113]). Studies have reported that METH downregulates the glutamate receptors. In the hippocampus, METH induction decreases the permeability and/or functionality of NMDARs and AMPARs, impairing spatial working memory ([@B235]). In the rat striatum and frontal cortex, METH changes the NMDAR and AMPAR subunit levels ([@B236]). Besides, the cortical iGluR antagonism protects against METH-induced striatal neurotoxicity ([@B75]). A few studies have correlated METH-induced neurotoxicity with mGluRs. Antagonism of mGluR1 by its selective antagonist JNJ16259685 \[(3,4-dihydro-2H-pyrano-\[2,3-b\]quinolin-7-yl)-(cis-4-methoxycyclohexyl) metha-none\] attenuates cocaine- and METH- treated behavioral effects in squirrel monkeys ([@B2]). In addition to mGluR1, mGluR5 receptors play an important role in METH reinforcement and METH-seeking behavior. An mGluR5 antagonist, 2-methyl-6-(phenylethynyl)-pyridine, dose-dependently reduces the reinforcing effects of METH under a fixed-ratio 1 and a progressive ratio schedule of reinforcement without altering overall responding for food. It also dose-dependently prevents the cue and drug-induced reinstatement of METH-seeking behavior ([@B70]). Another study reported that mGluR5 plays a role in the maintenance of place preference memory and that its negative allosteric modulators could be potentially used in METH addiction therapy ([@B88]).

### Amyloid Beta

Amyloid beta (Aβ) acts as a neurotoxic agent by initiating biochemical cascades that ultimately lead to synaptotoxicity and neurodegeneration ([@B263]). It can interrupt excitatory synaptic transmission and plasticity in the brain via the dysregulation of AMPARs and NMDARs ([@B79]). Recent research employing Aβ-induced neurotoxicity models have shown that the altered activity of NMDARs plays a major role in disease pathogenesis. Aβ enhances the activation of extrasynaptic NMDARs by decreasing neuronal glutamate uptake and inducing glutamate spillover ([@B274]). It binds to hippocampal neuron NMDAR subunits GluN1 and GluN2B ([@B126]; [@B127]). The GluN2B subunit is involved in regulating the action of Aβ oligomers by increasing intracellular Ca^2+^ in dendritic spines, resulting in the reduction of dendritic spine and synaptic density, which leads to early synaptic dysfunction ([@B224]). In an Aβ-induced model, synaptic alterations were mitigated by blocking glutamate from binding to NMDARs though the use of an NMDARs antagonist ([@B28]). Correspondingly, the stimulation of GluN2B by Aβ oligomer triggers the activation of MAPK and the subsequent downregulation of cAMP response element-binding protein (CREB) ([@B134]). Indeed, Aβ reduces BDNF signaling by impairing axonal transport, which leads to synaptic dysfunction ([@B198]). A recent report showed that inhibition of NMDARs prevents the Aβ-induced loss of BDNF function ([@B251]). In addition, through in an α7-nicotinic acetylcholine receptor (α7-nAChR)-dependent manner, Aβ oligomers induce the endocytosis of NMDARs ([@B240]). Likewise, α7-nAChRs are linked to the deregulation of NMDA signaling pathways ([@B213]; [@B224]). Interestingly, relatively low doses of NMDA-antagonists have been shown to reverse Aβ-induced synaptic disruption ([@B134]; [@B211]). Aβ downregulates the caspase-mediated loss of two synaptic proteins, PSD-95 and synaptophysin. It suppresses NR2A function and activates NR2B following the induction of caspase-8 and caspase-3 activities. On the other hand, MK-801 and ifenprodil (an NR2B antagonist) prevent Aβ-induced toxicity ([@B145]). In hippocampal neurons, Aβ oligomers disrupt axonal transport initiated by NMDAR-dependent mechanisms, and this is modulated by the enzyme glycogen synthase kinase-3β ([@B54]). In another study, the activation of Aβ-induced striatal-enriched protein tyrosine phosphatase was shown to lead to the dephosphorylation of tyrosine residues on NMDARs. Dephosphorylation of the GluN2B subunit correlates with increased NMDARs endocytosis and suppression of its synaptic function. On the other hand, reelin activates Src family tyrosine kinases and enhances tyrosine phosphorylation of the GluN2A and GluN2B subunits. Reelin signaling may prevent Aβ-induced NMDARs endocytosis and Src family tyrosine kinases activation ([@B60]). A proposed mechanism of Aβ-induced impairment in major types of signaling through NMDARs that leads to synaptic dysfunction is presented in **Figure [2](#F2){ref-type="fig"}**.

![Amyloid beta-induced synaptic dysfunction through NMDAR. Binding of Aβ to the NMDAR causes calcium overload in the synapse leading to impairment in various signaling pathways. Finally, these impairments cause synaptic dysfunction. PSD-95: Postsynaptic density protein 95; MAPKs: Mitogen-activated protein kinases; GSK-3β: Glycogen synthase kinase-3 beta; CREB: cAMP-response element binding protein; BDNF: Brain-derived neurotrophic factor; CaMKII: Calcium/calmodulin-dependent protein kinase II](fnmol-11-00307-g002){#F2}

Aβ-induced synaptic dysfunction has been attributed to the synaptic removal of AMPARs. Aβ-induced change in the subcellular distribution of Ca^2+^/calmodulin-dependent protein kinase II may drive the removal of AMPARs from the synaptic membrane by Aβ ([@B76]). Aβ initiates synaptic and memory deficits by removing GluA3-containing AMPARs from synapses ([@B207]). It disrupts mitochondrial trafficking, which may contribute to AMPAR removal as well as trafficking defects that cause synaptic inhibition ([@B215]). Furthermore, Aβ-induced dendritic spine loss and reductions in pre- and post-synaptic protein levels in hippocampal slice cultures can impair hippocampal LTP ([@B300]; [@B274]; [@B28]).

Aβ-induced ectopic NMDA and mGluR-mediated signaling coupled with caspase-3 activation may inhibit LTP and also facilitate long-term depression (LTD) ([@B95]). Within the synaptic space, membrane-bound Aβ oligomers accumulate and via a lateral diffusion process, gradually aggregate in order to form large non-mobile clusters. Aβ pathological clusters form complexes with mGluR5 receptors, which decreases the mobility of mGluR5 and causes its anomalous accumulation at the postsynaptic membrane. This is followed by calcium deregulation, synaptic disruption, and loss of NMDARs ([@B208]). In a transgenic model study, Aβ oligomer-cellular prion protein complexes activated mGluR5 at the neuronal surface, which led to the disruption of neuronal function ([@B259]). The downregulation of mGluR and desensitization of the frontal cortex in AD patients correlated with AD-related neuropathological variations. Furthermore, the chronic activation of mGluR5 increased NMDA-dependent Aβ neurotoxicity, whereas mGluR5 antagonism exhibited neuroprotective effects against Aβ excitotoxic processes and prevented impairments in learning, memory and synaptic density ([@B205]; [@B259]).

### Homocysteine

Homocysteine (Hcy), a sulfur-containing amino acid derived from the metabolism of methionine, is an independent risk factor for AD ([@B18]; [@B133]). As a known neurotoxic agent, Hcy is used to induce neurotoxicity. In several animal model studies, Hcy brought about synaptic dysfunction, oxidative stress, neurochemical imbalance, and apoptosis, resulting in cognitive impairment and neuronal cell death. Thus, an Hcy-induced neurotoxicity model might be suitable for the study of AD ([@B16],[@B17],[@B18]; [@B275]; [@B114]; [@B136]). Hcy has been shown to modulate glutamate receptors, which leads to various neurotoxic effects. The activation of Hcy-NMDAR-mediated extracellular signal-regulated kinase causes neuronal cell death. Further, it modulates hippocampal glutamate and the NMDAR/AMPAR ratio in a rat model of chronic unpredictable mild stress-induced depression ([@B197]; [@B144]; [@B173]; [@B196]). Moreover, Hcy modulates mGluRs. An mGluR1 antagonist produces neuroprotective effect in the Hcy-induced neurodegenerative model ([@B295]).

### β-*N*-methylamino-L-alanine

The non-proteinogenic amino acid β-*N*-methylamino-L-alanine (BMAA), was first identified in the seeds of *Cycas micronesica* in 1967 ([@B159]), though a wide range of cyanobacteria are now known to produce BMAA. Recently, the most common group of algae (diatoms) was also found to produce it ([@B55]). BMAA is considered one of the first environmental factors that contributes to the etiologies of AD, PD, and ALS ([@B310]). It is a common neurotoxin utilized in the study of neurodegeneration in cellular and animal models, specifically those for the study of ALS/Parkinsonism-dementia complex. BMAA causes neuroinflammation, oxidative stress, apoptosis and cognitive impairment ([@B30]; [@B147]; [@B220]; [@B310]; [@B178]; [@B8]; [@B247]; [@B128]; [@B194]). It elicits neurotoxicity by acting as an agonist for glutamate receptors such as AMPARs/KARs, NMDARs, and mGluR5 ([@B147]; [@B55]). BMAA causes a significant increase in Ca^2+^ influx and enhanced ROS production, while also disrupting mitochondrial activity in rat olfactory ensheathing cells ([@B45]). In addition, it interferes with neurotransmission in human neuroblastoma cells. BMAA alters alanine, aspartate, and glutamate metabolism and also modifies numerous neurotransmitters/neuromodulators, such as GABA and taurine ([@B65]). However, the mechanism of BMAA-induced neurotoxicity is not yet fully understood, and its role as a glutamate receptor agonist may in fact lead to excitotoxicity that hampers glutamate transport systems ([@B312]).

### 3-Nitropropionic Acid

3-Nitropropionic acid (3-NP) is a common neurotoxic agent used to study HD and is an irreversible inhibitor of mitochondrial complex-II. In the experimental animal model, it caused mitochondrial dysfunction, oxidative stress, biochemical imbalance, neuroinflammation, apoptosis, and autophagy, leading to neuronal cell death ([@B27]; [@B241]; [@B225]; [@B103]; [@B253]). 3-NP was shown to produce neurotoxicity via the modulation of glutamate receptors. One study has suggested that 3-NP produces a neurotoxic effect through GluN2B-containing NMDARs ([@B36]). In addition, the glutamate receptor antagonist, (2*R*)-amino-5-phosphonovaleric acid (AP5), negates the 3-NP-induced NMDAR-mediated second peak in ROS, mitochondrial fission, and cell death ([@B140]). The cannabinoid agonist WIN55,212-2 has been shown to produce a neuroprotective effect against 3-NP-induced striatal neurotoxicity via the induction of NMDARs hypofunction ([@B158]). Moreover, mGluR5 may be involved in 3-NP-induced neurotoxicity. In a study, MTEP produced neuroprotective activity in a 3-NP-induced neuronal injury model ([@B243]).

### Cuprizone

Cuprizone is a common neurotoxic agent indicated to induce neurotoxicity to study NDDs. It is particularly used to induce multiple sclerosis-like syndromes. In the experimental animal model, it has shown to cause demyelination, oxidative stress, neuroinflammation, and apoptosis leading to neuronal cell death ([@B77]; [@B313]; [@B239]; [@B216]; [@B203]; [@B219]). In the cuprizone model of demyelination, the NMDARs specific antagonist MK-801 delays remyelination. NMDARs plays a critical role in the regulation of oligodendrocyte precursor cell differentiation *in vitro* and remyelination in cuprizone model, which may provide a potential target for the treatment of demyelination disease ([@B132]). Another study reported that cuprizone treatment affected glutamate-receptors and -transporters differently in the gray and white matter areas of the brain, specifically, showed that it regulates the glutamate-aspartate transporter (*Slc1a3*) and neutral amino acid transporter A (*Slc1a4*) genes compared with other genes. Among the different NMDAR subunits, GluN2A was upregulated in the demyelinated corpus callosum (CC) and mGluR2 was downregulated in the demyelinated gray matter ([@B248]).

### Doxorubicin

Doxorubicin (DOX) is a known neurotoxic agent suitable for both *in vivo* and *in vitro* studies. In experimental models, DOX induction of neurotoxicity causes mitochondrial dysfunction, oxidative stress, neuroinflammation, apoptosis, cognitive impairments, and neuronal cell death ([@B231]; [@B237]; [@B43]). Several molecular studies have shown that DOX impairs glutamate receptors, leading to neuronal toxicity. In a DOX-induced neurotoxicity study, memantine was shown to counter neuronal cell death by blocking NMDARs ([@B107]). In addition, mGluR II and III activators produced neuroprotective effects on DOX-induced cellular injury ([@B106]). Furthermore, LTP and AMPARs impairment has been shown in DOX-treated animals. Compared to controls, the expression of the AMPAR subunit, GluA1, was significantly decreased, whereas the expression of the GluA2 subunit was significantly elevated ([@B7]). Another study showed that NMDARs and AMPAR might be involved in DOX-induced damage to DNA in neurons ([@B155]).

### Glucocorticoid

The hormone, GC, rises in concentration response to stress, which can cause neuronal loss ([@B118]). GC-induced neurotoxicity might be an appropriate model for the study of NDDs. It causes oxidative stress, memory impairment, neuronal cell death, and apoptosis ([@B53]; [@B149]; [@B212]; [@B296]; [@B290]) the latter through iGluRs and mGluRs ([@B149]). The stress-induced elevation of GC increases microglia proliferation through the activation of NMDARs. MK-801 has been shown to prevent the increase of microglia following the administration of exogenous GC corticosterone ([@B181]).

### Harmaline

Harmaline-induced neurotoxicity in animals also could be a robust model for the study of NDDs ([@B99]; [@B50]). Harmaline modulates both iGluRs and mGluRs ([@B121]; [@B99]). As an inverse agonist of NMDARs, it produces tremors ([@B58]). The synchronous activation of the olivocerebellar pathway and release of glutamate in the cerebellum (which acts on NMDARs and AMPARs) is proposed to be main cause of harmaline-induced tremors ([@B232]). In addition, the agonistic action of harmaline on mGluR1 produces motor disturbances ([@B121]). On the other hand, memantine produces neuroprotective and anti-tremorgenic activities against harmaline-induced tremors and neurodegeneration ([@B99]).

### Pentylenetetrazol

The tetrazole derivative, PTZ, causes convulsions in mice, rats, cats, and primates, likely by interfering with GABA-mediated inhibition. PTZ is best known for its use in the screening of antiepileptic drugs ([@B306]). It causes neuroinflammation and oxidative stress, which affects cognition. In addition, PTZ has been observed to cause amnesia in animal models ([@B189]; [@B199]; [@B57]). It is also known to modulate glutamate receptors. In a PTZ-induced kindling model of epilepsy, NMDARs are upregulated in both the hippocampus and cortex. KARs/AMPARs antagonists act as anticonvulsants against the tonic hind limb component of PTZ-induced seizures in developing rats ([@B262]; [@B61]; [@B210]). The group III mGluR agonist CPPG \[(RS)-*α*-cyclopropyl-4-phosphonophenylglycine\] has been shown to attenuate PTZ-induced seizures. Moreover, it increases glutamate concentrations in the hippocampus of non-kindled control rats ([@B152]). The effects of several neurotoxic agents on both iGluRs and mGluRs are listed in **Table [1](#T1){ref-type="table"}**.

###### 

Major impairing effects of several neurotoxic agents on iGluRs and mGluRs.

  Toxic agents     Major modulating effects                                                                                                  Reference
  ---------------- ------------------------------------------------------------------------------------------------------------------------- -----------------------------------
  MPTP             Upregulates mGluR5 and causes damages in dopaminergic and noradrenergic neurons                                           [@B218]; [@B157]
  MPP^+^           Activates NMDARs and dysregulates mGluR8; causes mitochondrial damage and neuronal cell death                             [@B33]; [@B105]
  Rotenone         Potentiates NMDA current; activates mGluR5; causes excitotoxicity and DNA damage                                          [@B280]; [@B281]
  METH             Impairs NMDARs, AMPARs, mGluR1, and mGluR5; causes striatal neurotoxicity and behavioral dysfunction                      [@B236]; [@B70]; [@B75]; [@B2]
  Homocysteine     Activates NMDARs and mGluR1; causes neuronal cell death                                                                   [@B197]; [@B295]
  BMAA             Activates AMPARs/KARs, NMDA and mGluR5 receptors; causes excitotoxic damage                                               [@B147]; [@B55]
  3-NP             Activates NMDARs and mGluR5; causes ROS elevation, mitochondrial fission, and cell death                                  [@B140]; [@B243]
  Cuprizone        Activates NMDARs; causes demyelination; affects glutamate-receptors and -transporters differently; downregulates mGluR2   [@B132]; [@B248]
  Doxorubicin      Dysregulates NMDARs, AMPARs, and mGluR II and III; causes neuronal injury                                                 [@B107]; [@B106]; [@B155]
  Glucocorticoid   Activates NMDARs and mGluR III; causes microglia proliferation and apoptosis                                              [@B149]; [@B181]
  Harmaline        Activates NMDARs, AMPARs, and mGluR1; produces tremors                                                                    [@B121]; [@B232]
  PTZ              Dysregulates NMDARs, AMPARs, and mGluR III; causes seizures                                                               [@B262]; [@B61]; [@B152]; [@B210]

3-NP: 3-Nitropropionic Acid; BMAA: β-N-methylamino-L-alanine; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP

\+

: 1-methyl-4-phenylpyridinium; METH: Methamphetamine; and PTZ: Pentylenetetrazol.

Agents That Act on iGluRs
-------------------------

### Ethanol

Chronic exposure to ethanol has complex and long-lasting effects on the function and expression of innumerable neuroreceptors as well as their modulators ([@B148]). Ethanol-induced neurotoxicity models have previously been used to study NDDs ([@B183]; [@B217]). *In vivo* and *in vitro* studies have shown that chronic ethanol exposure elevates *GluN1* and *GluN2B* gene expression and their polypeptide levels. In animal models, ethanol-induced neurotoxicity has been shown to cause oxidative stress, apoptosis, and neuroinflammation, ultimately causing neurodegeneration ([@B257], [@B258]; [@B183]; [@B246]; [@B5]; [@B270]). Ethanol has been shown to produce neurotoxicity in cellular studies on BV-2 microglia, PC12 cells, and HT22 cells ([@B34]; [@B301]; [@B97]). As a potent inhibitor of NMDARs, it acts on glutamate receptors and impairs the functionality of NMDARs and AMPARs. Moreover, ethanol inhibits glutamate receptor-mediated synaptic plasticity such as NMDA-dependent LTP ([@B277]; [@B175], [@B176]; [@B89]; [@B174]; [@B87]). The effect of alcohol and molecular changes within the regulatory process that modulates NMDARs functions, including factors that alter transcription, translation, post-translational modifications, and protein expression along with those that influence their interactions with different regulatory proteins (downstream effectors) constantly increases at the cellular level. Epigenetic dimension (i.e., histone modification-induced chromatin remodeling and DNA methylation that occurs in the process of alcohol-related neuroadaptation) is a key molecular mechanism in alcohol-mediated NMDARs alteration ([@B38]).

### Ammonia

An ammonia-induced neurotoxicity model uncovered potential therapeutic strategies ([@B82]). Elevated ammonia levels damage motor neurons through numerous means, including endoplasmic reticulum (ER) stress, cyclin-dependent kinase 5 activation, macroautophagy-endolysosomal pathway impairment, oxidative and nitrosative stress, neuronal hyperexcitability, and neuroinflammation ([@B192]). In order to produce neurotoxicity, ammonia modulates glutamate receptors and activates NMDARs which in turn leads to the following: (i) adenosine triphosphate (ATP) is depleted in the brain, causing glutamate release; (ii) calcineurin and dephosphorylation are activated and Na^+^/K^+^-ATPase is activated in the brain, increasing ATP consumption; (iii) mitochondrial function and calcium homeostasis are impaired at different levels, thus reducing ATP synthesis; (iv) calpain activation degrades microtubule-associated protein-2, thus altering the microtubular network; and (v) nitric oxide (NO) formation rises, reducing the activity of glutamine synthetase, thus decreasing the elimination of ammonia in the brain ([@B169]; [@B122]). In addition, through an excitatory amino acid transporter, ammonia mediates METH-induced increases in extracellular glutamate in order to cause excitotoxicity ([@B84]). Interestingly, NMDARs and AMPARs antagonists prevent ammonia-induced toxicity in experimental models ([@B169]; [@B85]).

### Hydrogen Peroxide

Hydrogen peroxide (H~2~O~2~) is a common neurotoxic agent that induces neurotoxicity in cellular models. Cell lines, including BV-2 microglia, PC12 cells, and SH-SY5Y cells, are ideal for studying H~2~O~2~-induced neurotoxicity. In experimental models, H~2~O~2~-induced neurotoxicity causes mitochondrial dysfunction, oxidative stress, cytotoxicity, apoptosis, and neuronal cell death ([@B86]; [@B171]; [@B102]; [@B163]; [@B308]; [@B156]; [@B186]) while it also modulates glutamate receptors. Exposure to H~2~O~2~ can activate normally silent NMDARs, potentially via the inhibition of redox-sensitive glutamate uptake. H~2~O~2~ affects synaptic transmission and oxidative stress through the activation of NMDARs ([@B20]). In striatal medium spiny neurons, the generation of AMPAR-dependent H~2~O~2~ is one source of retrograde signals that can block the release of DA ([@B19]).

### Cisplatin

Cisplatin (cis-diaminodichloroplatinum) was developed in the 1970s as the first platinum-based antineoplastic agent. Neurotoxicity, a common side effect of cisplatin leads to chemotherapy-induced peripheral neuropathy. An accumulation of cis-platinum in dorsal root ganglion neurons in the form of platinum-DNA adducts is thought to be a key mechanism driving such neurotoxicity ([@B311]). In addition, as a known neurotoxic agent, cisplatin is suitable for use in NDD models, because it is known to cause memory and learning impairment through oxidative stress and neuroinflammation ([@B167]; [@B190]; [@B309]; [@B41]). Cisplatin modulates glutamate receptors and induces neural activation through the central upregulation of AMPARs and NMDARs ([@B92]). NMDARs antagonist protects against cisplatin-induced depression ([@B130]).

### Lead

Lead (Pb) is a well-known neurotoxic agent that brings about cognitive deficits in animal models. As a neurotoxic agent in different study models, Pb caused oxidative stress, synaptic and cholinergic dysfunction, neuroinflammation, autophagy, apoptosis, cognitive deficits, and neuronal cell death ([@B195]; [@B294]; [@B44]; [@B161]; [@B249]; [@B291]). Pb-induced neurotoxicity may be based on the modulation of glutamate receptors, especially iGluRs. During synaptogenesis, it inhibits the functionality of NMDARs. Moreover, Pb exposure causes a decrease in the expression of AMPAR subunits (GluA1, GluA2, GluA3, and GluA4) with the observed decrease in GluA2 expression being particularly remarkable. Pb-induced neuronal cell death was rescued by three glutamate receptor antagonists: 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), MK-801, and 1-naphthyl acetyl spermine (a specific Ca^2+^-permeable AMPARs blocker) ([@B179]; [@B184]; [@B101]).

### Manganese

Manganese (Mn) can be employed in order to induce neurotoxicity in studies on NDDs, especially PD. Mn-induced neurotoxicity brings about mitochondrial dysfunction, oxidative and nitrosative stress, neuroinflammation, and apoptosis, leading to cell death in different animal and cellular models ([@B47]; [@B172]; [@B49]; [@B40]; [@B135]; [@B228]). It alters the functionality of glutamate receptors and it has been reported that Mn inhibits the functionality of NMDAR channels with an implication for psychiatric and cognitive impairment ([@B78]). Furthermore, by increasing extracellular glutamate levels and modifying the expression of NMDAR subunits, Mn induces nerve cell damage in mRNAs and proteins in rat striatum ([@B283]). In addition to NMDARs, it may also modulate AMPARs. Co-administration of the excitatory agonist, AMPA, with Mn enhances Mn-enhanced magnetic resonance imaging signals. However, this was attenuated by the co-administration of either the Na^+^ channel blocker tetrodotoxin (TTX), or the broad-spectrum Ca^2+^ channel blocker Ni^2+^ ([@B269]).

### Mercury

Mercury (Hg) is a naturally occurring heavy metal ([@B168]), and a well-known neurotoxic agent for inducing neurotoxicity. A Hg-induced neurotoxicity model is a powerful tool in the study of neurodegeneration. Hg-induced neurotoxicity in animals causes mitochondrial dysfunction, oxidative stress, neuroinflammation, and apoptosis, overall resulting in cognitive deficits and neuronal cell death ([@B116]; [@B21]; [@B3]). Hg-induced neuronal death is dependent on glutamate-mediated excitotoxicity. Hg has been found to affect NMDARs by increasing their expression and enhancing their responsiveness. The overactivation of NMDA-type glutamate receptors increases Ca^2+^ influx into neurons, which leads to the activation of important pathways involved in neuronal cell death. Furthermore, Ca^2+^ stimulates ROS generation through the mitochondrial pathway as a result of Hg-induced overactivation of NMDARs that take part in neuronal cell death ([@B67]; [@B285]; [@B168]; [@B64]).

### Melamine

Another powerful tool in the study of NDDs is melamine-induced neurotoxicity. In studies involving animal models, it has been shown to cause synaptic dysfunction and oxidative stress, leading to cognitive impairment ([@B10], [@B11]; [@B13]). In recent studies, it presynaptically altered the glutamatergic transmission of the hippocampal CA3-CA1 synapses *in vitro*. This alteration is likely linked to a modification to autophagy. Acute melamine exposure impaired spatial memory consolidation by disrupting hippocampal NMDAR-dependent LTD ([@B298]; [@B12]).

### Sodium Azide

NaN~3~ is a neurotoxic agent commonly used for neurotoxicity in both *in vivo* and *in vitro* models. It causes mitochondrial dysfunction, oxidative stress, neuroinflammation, apoptosis, and autophagy, ultimately leading to neuronal cell death ([@B222]; [@B302]; [@B187]; [@B223]). Upon the glutamate receptors modulation by NaN~3~ produces neurotoxicity. Studies have found that MK-801 blocks NaN~3~-induced cell death, signifying that NMDARs contributes to mediated cell death ([@B74]; [@B222]).

### Isoflurane

In experimental animal models, isoflurane brings about mitochondrial dysfunction, neuroinflammation, and apoptosis, leading to cognitive impairments and neuronal cell death ([@B137]; [@B96]; [@B138]; [@B245]; [@B279]; [@B286]). Furthermore, it has been observed to modulate glutamate receptors. One study has reported that NMDAR-mediated excitatory synaptic transmission is more sensitive to isoflurane than non-NMDAR-mediated excitatory synaptic transmission ([@B286]). In addition, at minimum alveolar concentrations, isoflurane causes GABA~A~ receptor antagonism and increases NMDARs inhibition ([@B185]).

### 3-Acetylpyridine

As a potent neurotoxic agent, 3-acetylpyridine (3-AP) readily induces neurodegeneration. 3-AP-induced neurotoxicity causes degeneration in the nigrostriatal dopaminergic system within experimental animal models. Furthermore, 3-AP-induced neurotoxicity can be used for both PD and spinocerebellar ataxia models ([@B56]; [@B276]; [@B104]; [@B1]; [@B160]). 3-AP modulates NMDARs and also yields neurotoxicity. Pre-exposure to subtoxic concentrations of NMDA enhances 3-AP toxicity, but the NMDARs antagonists, MK-801 or APV, as well as deprenyl, mazindol, and tetrahydrofolic acid, have no effect on 3-AP toxicity ([@B276]). Another study has suggested that thyrotropin-releasing hormone receptor agonists ameliorate 3-AP-induced ataxia in rats via NMDARs ([@B119]).

### 6-Hydroxydopamine

6-Hydroxydopamine (6-OHDA) is employed to induce PD and study the mechanism of dopaminergic neuron cell death in animal models. It is a selective agent for the nigrostriatal pathway. As 6-OHDA shares certain structural similarities with DA, it can enter dopaminergic neurons via DA transporters, and consequently cause toxicity ([@B226]). It produces diverse toxic effects, such as mitochondrial dysfunction and oxidative stress, apoptosis, neuroinflammation, and dopaminergic cell death ([@B37]; [@B139]; [@B226]; [@B254]; [@B80]; [@B201]; [@B267]; [@B63]; [@B153]; [@B177]; [@B52]; [@B143]; [@B293]; [@B299]; [@B164]). Disturbance of the dopaminergic system may also cause glutamatergic NMDARs imbalances in the brain ([@B83]). In addition, 6-OHDA dysregulates NMDAR functions. NMDARs antagonists increase dopaminergic neuronal survival and prevent a levodopa-induced abnormal motor response ([@B26]; [@B292]).

### Ketamine

Ketamine is considered to be a general anesthetic and is used extensively in pediatric surgery. It is an NMDARs antagonist and is increasingly employed in pre-clinical studies in order to induce psychosis in experimental models ([@B154]; [@B200]; [@B271]). As a neurotoxic agent, it is utilized in animal models to induce cognitive impairment. This produces diverse toxic effects such as oxidative stress and apoptosis, leading to cognitive impairment. Ketamine-induced cognitive impairment models have long been employed to study NDDs ([@B154]; [@B59]; [@B71]; [@B266]; [@B191]; [@B271]). Ketamine-induced neurotoxicity causes a use-dependent blockade of NMDARs. This excitatory synaptic blockade activity possibly causes the loss of responsiveness linked to ketamine anesthesia ([@B238]). Furthermore, in a rat model of ketamine-induced neurotoxicity, extended ketamine exposure produces an increase in the expression of NMDAR (GluN1) (compensatory upregulation). This permits a higher toxic influx of Ca^2+^ into neurons once ketamine is removed from the system, increasing the generation of ROS and neuronal cell death ([@B141]). In addition, ketamine modulates the AMPARs. However, ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the increase in AMPAR signaling that leads to ketamine antidepressant activity ([@B25]). Recently, ketamine-induced impairment of the AMPARs potentiator, PF-04958242, has been shown to affect the verbal learning and memories of healthy volunteers ([@B206]). In addition, an updated study was carried out with primary cultured cortical neurons and PC12 cells using a ketamine-induced neurotoxicity model ([@B142]).

### Colchicine

Colchicine is a plant alkaloid that is regarded as a potent inhibitor of physiological processes. It specifically binds to a receptor site on tubulin and blocks mitosis ([@B115]). It is one of the major neurotoxins used in the study of AD ([@B165]; [@B234]). Colchicine-induced neurotoxicity might be caused by glutamate receptor modulation. Colchicine-induced neuroinflammation leading to neurodegeneration in rats might be linked to NMDARs and therapy with memantine mitigates that toxicity ([@B233]).

### Bisphenol-A

As a neurotoxic agent, BPA mainly affects hippocampal neurogenesis and causes cognitive impairment in animal models ([@B35]; [@B256]; [@B62]). Various studies have reported that BPA affects glutamate receptors (NMDARs and AMPARs) and produces neurotoxicity ([@B288]; [@B289]; [@B287]). According to a recent study, GluN2A and GluA1 (LTP-related glutamate receptors) were significantly downregulated in BPA-exposed rats ([@B94]). iGluRs that modulate the actions of miscellaneous neurotoxic agents are summarized in **Table [2](#T2){ref-type="table"}**.

###### 

iGluRs that modulate the actions of miscellaneous neurotoxic agents.

  Toxic agents   Major modulating effects                                                                                    Reference
  -------------- ----------------------------------------------------------------------------------------------------------- ---------------------------
  Ethanol        Inhibits NMDARs and AMPARs; impairs motor and memory performance                                            [@B89]; [@B174]
  NH~3~          Activates NMDARs; reduces glutamine synthetase activity; decreases the elimination of NH~3~ in the brain.   [@B169]; [@B122]
  H~2~O~2~       Activates NMDARs and affects synaptic transmission and oxidative stress                                     [@B20]
  Cisplatin      Upregulates AMPARs and NMDARs; causes neuronal damage                                                       [@B92]
  Pb             Dysregulates AMPARs; causes synaptic dysfunctions and cell death                                            [@B179]; [@B184]; [@B101]
  Mn             Inhibits NMDARs and AMPARs; causes psychiatric and cognitive impairment                                     [@B78]; [@B269]
  Hg             Over activates NMDARs; increases Ca^2+^ influx into neurons                                                 [@B168]
  Melamine       Disrupts hippocampal NMDAR-dependent LTD                                                                    [@B298]; [@B12]
  NaN3           Activates NMDARs; causes cell death                                                                         [@B74]; [@B222]
  3-AP           Activates NMDARs; causes ataxia                                                                             [@B119]
  6-OHDA         Activates and dysregulates NMDAR function; causes motor complications and neuronal damage                   [@B26]; [@B292]
  BPA            Alters NMDARs and AMPARs                                                                                    [@B288], [@B287]; [@B289]

6-OHDA: 6-Hydroxydopamine; AMPARs: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors; LTD: Long-term depression; Mn: Manganese; NMDARs: N-methyl-D-aspartate receptors; NH

3

: Ammonia; NaN

3

: Sodium Azide; Hg: Mercury; and H

2

O

2

: Hydrogen Peroxide.

Concluding Remarks
==================

Apart from the transgenic model of NDDs, animal and cellular models that make use of neurotoxic agent-induced neurotoxicity are very popular in the study of disease progression and potential therapeutic drugs. However, numerous pharmaceutical research projects have so far failed to discover therapeutic drugs for NDDs using these toxic agent-induced models.

Currently, the use of receptors for targeting drug discovery is an efficient approach. Diversity in the class and structural features of glutamate receptors plays a large role in the pathogenesis of NDDs and serves as a target for drugs for treating neurological disorders. We discussed here numerous neurotoxic agents that are capable of producing neuronal toxicity by altering the functionality of glutamate receptors. Several covered neurotoxic agents produced neuronal toxicity mainly by activating receptors where both ionotropic and metabotropic receptors are important for inducing neurotoxicity. As iGluRs are non-selective cation channels, upon binding to an agonist, they permit the passage of Na^+^ and K^+^, and in certain cases, limited quantities of Ca^2+^. Hence, excitotoxicity that induces neuronal damage might be one of the principal mechanisms of neurotoxic agents. On the other hand, upon an agonist binding to mGluRs, a post-synaptic membrane-bound G-protein is activated. This triggers a second messenger system that opens an ion channel for the mediation of signals. G-protein activation also triggers functional changes within the cytoplasm, culminating in gene expression and protein synthesis and specifically, the activation of diverse signaling systems. The mechanic progression of neuronal damage exerted by neurotoxic agents might be complex because the agents act on metabotropic receptors.

Many studies that use neurotoxic agent-induced models reveal the receptors modulating effects, but do not correlate with associated molecular signaling pathways. Despite knowing the mechanism involving glutamate receptors and neurotoxic agents, future studies focusing on glutamate receptors should still be designed. First, considering the pathological actions of currently available neurotoxic agents, the development of new natural, semi-synthetic, and synthetic neurotoxic agents is recommended. Second, more studies using the potent neurotoxic agents discussed here should be conducted. Third, molecular docking should be performed in order to identify receptor-neurotoxic agent interaction at the molecular level based on updated structural features. Finally, laboratory-based *in vitro* studies in which neuronal cell lines are used should be designed. In addition, *in vivo* studies on model organisms to identify molecular signals that impair by neurotoxic agents should be designed and conducted. By understanding the neurotoxic agent-induced neurotoxicity model, screening of agonist, antagonist and allosteric modulators might be of value for NDD therapy. In summary, by targeting glutamate receptors and their associated signals, a neurotoxic agent-induced neurotoxicity model has the potential to correlate a neurotoxic agent with disease pathophysiology. By considering that pathophysiology, the design and discovery of new and modified therapeutic molecules may be a feasible treatment strategy for NDD therapy.
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α-Syn

:   alpha-synuclein

6-OHDA

:   6-Hydroxydopamine

AD

:   Alzheimer's disease

AMPARs

:   α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors

Aβ

:   amyloid beta

Al

:   aluminum

BMAA

:   β-*N*-methylamino-L-alanine

BPA

:   bisphenol A

DomA

:   domoic acid

DZP

:   diazepam

DOX

:   doxorubicin

DSP-4

:   \[N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine\]

GC

:   glucocorticoid

Hg

:   mercury

Hcy

:   homocysteine

GiluRs

:   ionotropic glutamate receptors

KARs

:   kainate receptors

LTP

:   long term potentiation

mGluRs

:   metabotropic glutamate receptors

MPTP

:   1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

MTEP

:   3-\[(2-methyl-1,3-thiazol-4-yl) ethynyl\]pyridine

Mn

:   manganese

METH

:   methamphetamine

NDDs

:   neurodegenerative diseases

NMDARs

:   N-methyl-D-aspartate receptors

NaN~3~

:   sodium azide

PD

:   Parkinson's disease

PTZ

:   pentylenetetrazol
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